Enfortumab Vedotin
Enfortumab Vedotin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Muscle-invasive Bladder Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
4 项
已进入 III/IV 期
20 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Astellas Pharma Global Development, Inc.
- H. Lee Moffitt Cancer Center and Research Institute
- Emory University
- University of Texas Southwestern Medical Center
- Fox Chase Cancer Center
- Peking University Third Hospital
- Mayo Clinic
- Spanish Oncology Genito-Urinary Group
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、西班牙、澳大利亚、Brazil、加拿大、Czechia、丹麦、法国、德国、Hungary、意大利
正在招募患者的 Enfortumab Vedotin 研究
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
II 期招募中美国NCT06553885Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
II 期招募中美国NCT05756569Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
I 期 / II 期招募中美国NCT06394570Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
II 期招募中美国NCT07221942EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
II 期招募中中国NCT07647289Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
II 期招募中美国NCT06104618Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
不适用招募中西班牙NCT06724159Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
II 期招募中中国NCT07309770Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
II 期招募中美国NCT06041503A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
III 期招募中美国澳大利亚Brazil加拿大NCT07218380Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
II 期 / III 期招募中美国NCT06493552Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
I 期招募中美国NCT04878029Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
II 期招募中美国NCT06311214Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
IV 期招募中美国NCT06764095Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy
II 期招募中日本NCT07347314Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
I 期 / II 期招募中美国NCT05126472KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
I 期 / II 期招募中美国Chile法国IsraelNCT07232602Study of EV for Recurrent Endometrial Carcinoma
II 期招募中美国NCT07139977Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
II 期招募中美国NCT07087860An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
III 期招募中美国澳大利亚Brazil加拿大NCT07720284Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
II 期招募中美国NCT05775471Probiotics in Advanced Urothelial Carcinoma
II 期招募中中国NCT06904573Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)
不适用招募中德国NCT07855926Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
II 期招募中美国NCT06356155
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。